ENTITY

Ergomed (ERGO LN)

18
Analysis
Health Care • United Kingdom
Ergomed provides specialized services to the pharmaceutical and biotechnology industries, focusing on clinical development, trial management, and pharmacovigilance. The company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV), offering solutions for all phases of clinical trials and post-approval drug safety. Ergomed was founded in 1997 and is headquartered in Guildford, United Kingdom.
more
bullish•Ergomed
•18 Nov 2022 20:43•Issuer-paid

Ergomed - Two key management changes

In a strategic move to support its business development plans and digitisation efforts, Ergomed has announced two senior appointments to its...

Share
bullish•Ergomed
•30 Sep 2022 16:22•Issuer-paid

Ergomed - Poised for a strong FY22

Ergomed released full H122 accounts following its July 2022 trading update, the key takeaway of which was the sustained strong momentum across both...

Share
bullish•Ergomed
•27 Jul 2022 22:46•Issuer-paid

Ergomed - Sustained growth momentum in H122

Ergomed’s H122 trading update re-emphasised its robust business model and resilient growth despite the challenging macro environment. Revenues grew...

Share
bullish•Ergomed
•27 Apr 2022 16:24•Issuer-paid

Ergomed - Healthy fundamentals for 2022

Ergomed’s FY21 results showed that adjusted EBITDA of £25.4m was ahead of our estimate of £24.0m and consensus of £23.4m. A strong order book...

Share
bullish•Ergomed
•03 Feb 2022 17:48•Issuer-paid

Ergomed - Healthy CRO segment rebound confirmed

Ergomed released its 2021 trading update. Total 2021 revenues are expected to be approximately £118.6m, up 37.3% y-o-y (our and the consensus...

Share
x